| Cost-effectiveness of biologics in polyarticular-course juvenile idiopathic arthritis patients unresponsive to disease-modifying antirheumatic drugs. | |
| | |
MedLine Citation:
|
PMID: 20740607 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
OBJECTIVE: Juvenile idiopathic arthritis (JIA) is the most common chronic pediatric rheumatic disease and can have long-term effects leading to disability in adulthood. Biologics are a new class of drugs increasingly used to treat JIA. The primary study objective was to determine the incremental costs of biologics per additional responder compared to conventional treatment (methotrexate). METHODS: A separate decision model was created for etanercept, infliximab, adalimumab, and abatacept. The study population consisted of polyarticular-course JIA patients with a prior inadequate response or intolerance to disease-modifying antirheumatic drugs (DMARDs). The effectiveness measure was the proportion of patients who had a treatment response at 1 year according to the American College of Rheumatology (ACR) Pediatric 30 (Pedi 30) improvement criteria. Direct and indirect costs were calculated in 2008 Canadian dollars. Incremental cost-effectiveness ratios and 95% confidence intervals (95% CIs) were calculated for each biologic agent using probabilistic sensitivity analyses. RESULTS: The additional costs per additional ACR Pedi 30 responder at 1 year were $26,061 (95% CI $17,070, $41,834), $46,711 (95% CI $30,042, $75,787), $16,204 (95% CI $11,393, $22,608), and $31,209 (95% CI $16,659, $66,220) for etanercept, adalimumab, abatacept, and infliximab, respectively. CONCLUSION: Biologics are more effective than methotrexate in achieving a short-term response in JIA patients with prior inadequate responses to DMARDs; however, this comes at a high annual cost. Adequate long-term data with respect to both safety and effectiveness are not currently available, nor are utility estimates. Such data will be important to estimate value for money for treating JIA with biologic drugs over the long term. |
| | |
Authors:
|
Wendy J Ungar; Vania Costa; Rebecca Hancock-Howard; Brian M Feldman; Ronald M Laxer |
Related Documents
:
|
10125317 - A better pill to swallow. 17183637 - A comparative study on the cost of new antibiotics and drugs of other therapeutic categ... 6846347 - Inexpensive microcomputer for intravenous admixture service applications. 10155327 - Once-daily aminoglycoside administration in gram-negative sepsis. economic and practica... 16086557 - Susceptibility to some antifungal drugs of vaginal lactobacilli isolated from healthy w... 9677787 - Application of federal law to compounding of prescription orders. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Arthritis care & research Volume: 63 ISSN: 2151-4658 ISO Abbreviation: Arthritis Care Res (Hoboken) Publication Date: 2011 Jan |
Date Detail:
|
Created Date: 2011-01-05 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101518086 Medline TA: Arthritis Care Res (Hoboken) Country: United States |
Other Details:
|
Languages: eng Pagination: 111-9 Citation Subset: IM |
Copyright Information:
|
Copyright © 2011 by the American College of Rheumatology. |
Affiliation:
|
The Hospital for Sick Children and University of Toronto, Toronto, Ontario, Canada. wendy.ungar@sickkids.ca |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs ...
Next Document: Associations with digital ulcers in a large cohort of systemic sclerosis: results from the Canadian ...